GlassScriptPhysician profile
Francesca Ceci
NPI 1225666431
$17,732.39
in general payments reported to CMS, 2019-2025
25 companies · $3,611 in 2025
The $3,611 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,491 · 2023: $8,144 · 2024: $2,486 · 2025: $3,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,657 · Education: $4,710 · Consulting Fee: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,656.77 |
| Education | $4,709.72 |
| Consulting Fee | $875.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $4,870.99 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $3,094.93 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $1,618.48 | 2023-2025 | Zoryve |
| Abbvie INC. | $1,096.83 | 2022-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $1,061.38 | 2022-2025 | |
| Leo Pharma INC. | $778.72 | 2024-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $678.80 | 2022-2025 | Dupixent |
| Galderma Laboratories, L.P. | $663.29 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Incyte Corporation | $586.96 | 2023-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $584.36 | 2023-2025 | Jublia, Cabtreo, Targretin |
| Amgen INC. | $467.64 | 2022-2025 | Otezla, Otezla |
| Ucb, INC. | $430.25 | 2024-2025 | Bimzelx |
| Journey Medical Corporation | $366.01 | 2022-2025 | |
| Janssen Biotech, INC. | $283.85 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $208.11 | 2022-2023 | Sotyktu |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $183.14 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $171.49 | 2024-2025 | |
| Epi Health, LLC | $141.37 | 2022 | |
| Lilly USA, LLC | $114.13 | 2024-2025 | Ebglyss, Taltz |
| Mayne Pharma Commercial LLC | $107.31 | 2023 | |
| Pfizer INC. | $83.70 | 2025 | |
| Sanofi-Aventis U.S. LLC | $59.99 | 2023 | |
| Botanix Sb INC | $34.39 | 2025 | Sofdra |
| Almirall LLC | $25.52 | 2025 | Seysara |
| Ani Pharmaceuticals, INC. | $20.75 | 2025 | Oxistat |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesca Ceci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.